Aryan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 41 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.23 Cr
- Revenue Growth -58.83%
- Profit Growth -26.11%
- Ebitda -66.63%
- Net Worth 2.66%
- Total Assets 2.57%
About Aryan Pharmaceuticals
Aryan Pharmaceuticals Pvt Ltd (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 June 1983 and has a history of 41 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.23 Cr.
Rinkesh Sheth and Suresh Sheth serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239MH1983PTC030196
-
Company No.
030196
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Jun 1983
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Aryan Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rinkesh Sheth
|
Director | 01-Mar-2007 | Current |
|
Suresh Sheth
|
Director | 01-Feb-1993 | Current |
Financial Performance of Aryan Pharmaceuticals.
Aryan Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 58.83% decrease. The company also saw a substantial fall in profitability, with a 26.11% decrease in profit. The company's net worth moved up by a moderate rise of 2.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aryan Pharmaceuticals?
Unlock access to Aryan Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹12.27 M
₹0
Charges Breakdown by Lending Institutions
- Dena Bank : 1.01 Cr
- The Msfc : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Oct 1999 | Dena Bank | ₹0.22 M | Open |
| 26 Jun 1998 | Dena Bank | ₹2.90 M | Open |
| 27 Aug 1997 | Dena Bank | ₹0.85 M | Open |
| 12 Oct 1995 | Dena Bank | ₹5.60 M | Open |
| 12 Oct 1995 | Dena Bank | ₹0.50 M | Open |
How Many Employees Work at Aryan Pharmaceuticals?
Unlock and access historical data on people associated with Aryan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aryan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aryan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.